Genome Research Technology Offers

Covid-19 Innovation Challenges by Innoget posted this:

Expertise in molecular biology either experimentally or computationally The Institut de Biotecnologia i de Biomedicina (IBB) was created in 1970 as a research institute of the Universitat Autònoma de Barcelona (UAB) to promote fundamental biological research. In the year 2000, the focus of research evolved towards the Biotechnology and Biomedicine fields, with the aim of advancing scientific findings into translational results. At present, the Institute hosts 18 research groups organised into 3 programmes and working in 7 areas of expertise: • Bioinformatics • Cellular Biology • Structural Biology • Genomics • Immunology • Microbiology • Proteomics. This multidisciplinary character, one of the most relevant characteristics of the IBB, allows for a broad approach to biological problems, both basic and applied. The IBB is also highly engaged in academic training at the undergraduate and postgraduate levels.

IBB-UAB posted this:

Expertise in molecular biology either experimentally or computationally The Institut de Biotecnologia i de Biomedicina (IBB) was created in 1970 as a research institute of the Universitat Autònoma de Barcelona (UAB) to promote fundamental biological research. In the year 2000, the focus of research evolved towards the Biotechnology and Biomedicine fields, with the aim of advancing scientific findings into translational results. At present, the Institute hosts 18 research groups organised into 3 programmes and working in 7 areas of expertise: • Bioinformatics • Cellular Biology • Structural Biology • Genomics • Immunology • Microbiology • Proteomics. This multidisciplinary character, one of the most relevant characteristics of the IBB, allows for a broad approach to biological problems, both basic and applied. The IBB is also highly engaged in academic training at the undergraduate and postgraduate levels.

Pascal Mayer posted this:
CEO at Alphanosos

Alphanosos rapid discovery technology against COVID 19 Alphanosos’ AI guided rapid discovery technology, validated in antimicrobials and anticancer, is expected to develop within 3 weeks of experimental work with a virology partner an anti-COVID-19 treatment composed of a synergistic mix of extracts of edible plants, chosen for being available in large amounts and with good traceability. Such treatment is, therefore, and also thanks to the innovative elaboration process, immediately available to enter large curative clinical trials, to be followed by country-wide deployment in a matter of weeks, for curative and for preventive goals (because of safety which is guaranteed by the edible nature of the mix).

Universitat Politècnica de Catalunya - UPC posted this:

New nanostructured material for tissue regeneration A new ion release system for revascularization and tissue regeneration based of calcium phosphate glass nanoparticles has been patented and developed. Partners to further develop the technology and/or to establish commercial agreements along with technical cooperation are sought.

Yissum - Research Development Company of the Hebrew University posted this:

Diagnosis & Rehabilitation of Language Disorders in Children, Using a Self-Operated Tablet Based App Diagnosis & Rehabilitation of Language Disorders in Children, Using a Self-Operated Tablet Based App Project ID : 19-2019-8746

Yissum - Research Development Company of the Hebrew University posted this:

Enhanced Secretion of Proteins by Tag-Cleaving Cellular System Enhanced Secretion of Proteins by Tag-Cleaving Cellular System Project ID : 6-2019-8747

LUCIA CORAL posted this:
Knowledge Tranfer Manager at National Cancer Institute CRO Aviano

Predictive Kit to identify patients non responding to platinum therapy Predictive Kit to identify patients non responding to platinum therapy. 10 gene signature as a predictive biomarker for platinum treatment against different cancer types. The invention consists in quantifying the expression of 10 genes from tumor cells to detect patients eligible for platinum treatment at higher risk of developing drug resistance and disease progression. Drugs such as cisplatin, oxaliplatin and carboplatin are used to treat various types of worldwide common cancer, but resistance is a frequent event. Patient stratification based on tumor gene expression profile allows to personalize treatment reducing side effects and costs.

University of Granada (OTRI) posted this:

Method for diagnosing Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia (HHT) is a rare and genetic disease in which a disorder in angiogenesis exists. A new method for the molecular diagnosis of this disease has been developed. It is based on the quantification of a set of microRNAs (miRNAs) transported by plasma exosomes, and in addition, this set allows diagnosing different variants of the disease. This new method has the advantage of providing new biomarkers that allow a rapid and reliable diagnosis of HHT, since the current methods are not valid for all the patients affected with HHT.

Yissum - Research Development Company of the Hebrew University posted this:

Platform for Neutrophil Specific Targeting as a Mode of Immunotherapy Dr. Zvika Granot, from the School of Medicine-IMRIC-Developmental Biology and Cancer Research, is working on a innovative approach for Neutrophil specific targeting of TGF-beta signaling as a novel anti-cancer therapy (see attached summary and several papers) Project ID : 6-2015-4241

Yissum - Research Development Company of the Hebrew University posted this:

Personalized Phage Therapy: A New Paradigm for Combating Antibiotic Resistance Infectious Disease A New Paradigm for Combating Infectious Disease in the Age of Antibiotic Resistance. Phage Therapy offers significant advantages: 1) Natural- Harnessing nature’s own enemy against bacteria 2) Smart kinetics Phages grow with bacteria and disappear in its absence 3) Can be manipulated (unlike antibiotics) Engineered / evolutionary developed 4) Efficient against biofilm Chain reaction of the phages 5) Do not harm the microbiome Highly specific to the target pathogen. Hazan's approach for a Personalized Phage Therapy suggests an adaptive and dynamic cocktail of phages and antibiotics , that are specially tailored using AI and machine learning prediction. Hazan et.al. offer a constantly increasing “Bank” of phages. Project ID : 43-2019-10746

Yissum - Research Development Company of the Hebrew University posted this:

Novel Drug Delivery System of Large Molecules for Localized Sustained Release Novel Drug Delivery System of Large Molecules for Localized Sustained Release Project ID : 6-2018-4643

Yissum - Research Development Company of the Hebrew University posted this:

Novel Chimeric System for Targeted Killing of Lymphocytic Cancer Cells Novel Chimeric Protein utilizing components of the Ubiquitin-Proteasome System for targeted killing of Lymphocytic Cancer Cells Project ID : 6-2018-4687

Yissum - Research Development Company of the Hebrew University posted this:

New Methodology to Control Calcium Carbonate Morphology and Material State New Methodology to Control Calcium Carbonate Morphology and Material State Project ID : 6-2018-4599

Yissum - Research Development Company of the Hebrew University posted this:

New Target for the Treatment of Abdominal Obesity New target for the treatment of obesity and abdominal obesity by inhibiting the FGFR3 receptor signalling pathway Project ID : 7-2018-4658

Yissum - Research Development Company of the Hebrew University posted this:

Novel Method for Identifying Personalized Anti-Cancer Drug Combinations NanoCode - Identifying Best Fit Cancer Drug Combinations In-Vivo Project ID : 6-2019-6704

Genome Research Technology Offers

Innovation Resources

Sitemaps

Support

Company

Top Posts Categories

Recognitions

Genome Research Technology Offers

Recognitions

Follow us